Welcome!

News Feed Item

Aeolus Announces Second Quarter Financial Results for Fiscal Year 2017

MISSION VIEJO, CA--(Marketwired - May 15, 2017) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage and infection announced today financial results for the three months ended March 31, 2017.

The company reported net loss of $1,035,000 or $0.01 per share for the three months ended March 31, 2017. This compares to a net loss (before extraordinary items) of $629,000 or $0.01 per share for the three months ended March 31, 2016. The increase in net loss was primarily attributable to pre-IND work on AEOL 11114, the Company's compound in development for the treatment of Parkinson's disease and lower revenues from the Biomedical Advanced Research and Development Authority ("BARDA").

"During the quarter, we initiated a Phase 1 safety study of AEOL 10150 in healthy volunteers, completed manufacturing optimization and oral formulation development work on AEOL 11114 for Parkinson's disease, and reported positive results in an animal model of Cystic Fibrosis with inhaled AEOL 20415," stated John L. McManus, President and Chief Executive Officer. "Although we were disappointed with BARDA's notification in March that it had elected not to exercise additional options under the contract at this time, we are continuing work in process under the contract through its expiration in May 2019. In addition, we are submitting proposals to and have received indications of interest from other government agencies to expand the funding of AEOL 10150 as a medical countermeasure against the pulmonary effects of radiation exposure and sulfur mustard gas exposure."

Results of Operations for the Three Months Ended March 31, 2017

Revenue for the three months ended March 31, 2017 was $129,000, which compares to $565,000 for the three months ended March 31, 2016. The revenue is from the BARDA Contract and the decline in revenue is primarily attributable to a lower level of activity under that contract.

Research and Development ("R&D") expenses increased $93,000, or 19%, to $594,000 for the three months ended March 31, 2017 from $501,000 for the three months ended March 31, 2016. The increase is primarily attributable to manufacturing optimization and oral formulation development work for AEOL 11114.

General and administrative ("G&A") expenses decreased $123,000, or 18%, to $570,000 for the three months ended March 31, 2017 from $693,000 for the three months ended March 31, 2016. The decrease is primarily attributable to lower accounting and legal fees related to SEC filing requirements.

Results of Operations for the Six Months Ended March 31, 2017

Revenue for the six months ended March 31, 2017 was $212,000, which compares to $870,000 for the six months ended March 31, 2016. The revenue is from the BARDA Contract and the decline in revenue is primarily attributable to a lower level of activity under that contract.

Research and Development ("R&D") expenses increased $89,000, or 9%, to $1,082,000 for the six months ended March 31, 2017 from $993,000 for the six months ended March 31, 2016. The increase is primarily attributable to manufacturing optimization and oral formulation development work for AEOL 11114.

General and administrative ("G&A") expenses decreased $2,000 to $1,252,000 for the six months ended March 31, 2017 from $1,254,000 for the six months ended March 31, 2016. The decrease is primarily attributable to lower investor relations fees.

As of March 31, 2017, the Company had approximately $981,000 in cash and cash equivalents and 152,085,825 common shares outstanding. The Company had accounts receivable of $603,000 and accounts payable of $638,000 on March 31, 2017.

Aeolus has filed today with the SEC its Quarterly Report on Form 10-Q for the quarter ended March 31, 2017. Aeolus urges its investors to read this quarterly filing as well as its Annual Report on Form 10-K, also filed with the SEC, for further details concerning the Company. The Quarterly Report on Form 10-Q and the Annual Report on Form 10-K are also available on the Company's website, at www.aolsrx.com.

About AEOL 10150

AEOL 10150 is a superoxide dismutase (SOD) mimic being developed for the treatment/mitigation of lung damage from exposure to chemical and radiological insults and to reduce/prevent lung damage in patients with Idiopathic Pulmonary Fibrosis (IPF) and in cancer patients receiving radiation therapy. AEOL 10150 protects tissue from damage and increases survival in animal models of lung damage after exposure to radiation toxic chemicals, agents that induce inflammation, and trauma by mitigating and/or preventing cell death, inflammation and fibrosis through its action on oxidative stress (Reactive Oxygen Species, or "ROS") and regulation of growth factors and chemokines including PTEN, TGF-β1, HIF-1α, TNF-α and IL-6, as well as impacting subsequent signaling pathways associated with ROS production, apoptosis and fibrosis such as NADPH-oxidase (Nox-4), PTEN, PI3K/p-Akt and p53/Bax. AEOL 10150 has been shown to improve survival and mitigate pulmonary damage in rodent models of SMG, chlorine gas and radiation exposure and in a nonhuman primate (NHP) model of whole thorax lung irradiation (WTLI). Given these promising results, Aeolus is developing AEOL10150 for the mitigation and/or treatment of pulmonary injury resulting from SMG exposure.

AEOL 10150 has performed well in animal safety studies, was well tolerated in two human clinical trials and is currently being tested in a third human study. Aeolus has received "Orphan Drug" designation for use in treating Lung ARS, Idiopathic Pulmonary Fibrosis and Amyotrophic Lateral Sclerosis and has active IND's for the Lung ARS and ALS indications. Preparations are currently underway to make IND filings for Idiopathic Pulmonary Fibrosis, Cancer Radiation Therapy and Pulmonary Effects of Sulfur Mustard Gas Exposure.

About Aeolus Pharmaceuticals

Aeolus Pharmaceuticals is developing a platform of novel compounds, for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. Its lead compound, AEOL 10150, is being developed for the treatment of Idiopathic Pulmonary Fibrosis and as a treatment to reduce side effects caused by radiation toxicity and improve local tumor control in cancer therapy. These development efforts have been aided by substantial funding for toxicology, manufacturing, and preclinical and clinical studies from the US Department of Health and Human Services, for the development of AEOL 10150 as a medical countermeasure against chemical and radiological weapons, where its initial target indications are as a protective agent against the pulmonary effects of radiation exposure and sulfur mustard gas exposure. The Company is also developing AEOL 11114 as a treatment for Parkinson's Disease and AEOL 20415 as a treatment for cystic fibrosis and diseases that have developed a resistance to existing antibiotic and anti-viral therapies. For more information, please visit Aeolus's corporate website at www.aolsrx.com.

Forward-Looking Statements

The statements in this press release that are not purely statements of historical fact are forward-looking statements. Such statements include, but are not limited to, those relating to Aeolus' product candidates, as well as its proprietary technologies and research programs, a potential phase 1 study in healthy normal volunteers, the BARDA Contract, and the expected use of proceeds from the financing. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Aeolus' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Important factors that could cause results to differ include risks associated with uncertainties of progress and timing of clinical trials, scientific research and product development activities, difficulties or delays in development, testing, obtaining regulatory approval, the need to obtain funding for pre-clinical and clinical trials and operations, the scope and validity of intellectual property protection for Aeolus' product candidates, proprietary technologies and their uses, and competition from other biopharmaceutical companies, and whether BARDA exercises one or more additional options under the BARDA Contract. Certain of these factors and others are more fully described in Aeolus' filings with the Securities and Exchange Commission, including, but not limited to, Aeolus' Annual Report on Form 10-K for the year ended September 30, 2016. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

                                                                            
                        AEOLUS PHARMACEUTICALS, INC.                        
                   CONDENSED CONSOLIDATED BALANCE SHEETS                    
                                 (Unaudited)                                
               (In thousands, except share and per share data)              
                                                                            
                                                    March 31,    September  
                                                       2017       30, 2016  
                                                   ------------ ------------
                      ASSETS                                                
Current assets:                                                             
  Cash and cash equivalents                        $       981  $     3,155 
  Accounts receivable                                      603          750 
  Prepaid expenses and other current assets                149          230 
                                                   ------------ ------------
    Total current assets                                 1,733        4,135 
                                                                            
Investment in CPEC LLC                                      32           32 
                                                   ------------ ------------
    Total assets                                   $     1,765  $     4,167 
                                                   ============ ============
                                                                            
  LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)                            
Current liabilities:                                                        
  Accounts payable and accrued expenses            $       638  $       972 
                                                   ------------ ------------
    Total current liabilities                              638          972 
                                                                            
                                                   ------------ ------------
    Total liabilities                                      638          972 
                                                                            
Commitments and Contingencies (Note H)                                      
                                                                            
Stockholders' equity:                                                       
  Preferred stock, $.01 par value per share,                                
   10,000,000 shares authorized:                                            
  Series A nonredeemable convertible preferred                              
   stock, 1,250,000 shares authorized as of March                           
   31, 2017 and September 30, 2016, respectively;                           
   no shares issued and outstanding as of March                             
   31, 2017 and September 30, 2016                           -            - 
  Series B nonredeemable convertible preferred                              
   stock, 1,600,000 and 1,600,000 shares                                    
   authorized as of March 31, 2017 and September                            
   30, 2016, respectively; 526,080 and 526,080                              
   shares issued and outstanding as of March 31,                            
   2017 and September 30, 2016                               -            - 
  Series C nonredeemable convertible preferred                              
   stock, 5,000 and zero shares authorized as of                            
   March 31, 2017 and September 30, 2016,                                   
   respectively; 4,500 and zero shares issued and                           
   outstanding as of March 31, 2017 and September                           
   30, 2016                                                  -            - 
  Common stock, $.01 par value per share,                                   
   200,000,000 shares authorized; 152,085,825                               
   shares issued and outstanding as of March 31,                            
   2017 and September 30, 2016                           1,520        1,520 
  Additional paid-in capital                           191,917      191,863 
  Accumulated deficit                                 (192,310)    (190,188)
                                                   ------------ ------------
    Total stockholders' equity (deficit)                 1,127        3,195 
                                                   ------------ ------------
    Total liabilities and stockholders' equity                              
     (deficit)                                     $     1,765  $     4,167 
                                                   ============ ============
                                                                            
                                                                            
                        AEOLUS PHARMACEUTICALS, INC.                        
              CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS               
                                (Unaudited)                                 
                    (In thousands, except per share data)                   
                                                                            
                                     Three months Ended   Six Months Ended  
                                          March 31,           March 31,     
                                     ------------------- -------------------
                                       2017      2016      2017      2016   
                                     --------- --------- --------- ---------
Revenue:                                                                    
 Contract revenue                    $    129  $    565  $    212  $    870 
                                                                            
Costs and expenses:                                                         
 Research and development                 594       501     1,082       993 
 General and administrative               570       693     1,252     1,254 
                                     --------- --------- --------- ---------
  Total costs and expenses              1,164     1,194     2,334     2,247 
                                     --------- --------- --------- ---------
Loss from operations                   (1,035)     (629)   (2,122)   (1,377)
                                                                            
Interest expense                            -         -         -      (285)
                                     --------- --------- --------- ---------
Net loss                               (1,035)     (629)   (2,122)   (1,662)
Deemed dividend on Series C                                                 
 preferred stock                            -     1,906         -     2,486 
                                     --------- --------- --------- ---------
Net loss attributable to common                                             
 stockholders                        $ (1,035) $ (2,535) $ (2,122) $ (4,148)
                                     ========= ========= ========= =========
                                                                            
Net loss per weighted share                                                 
 attributable to common                                                     
 stockholders:                                                              
 Basic (Note E)                      $  (0.01) $  (0.02) $  (0.01) $  (0.03)
                                     ========= ========= ========= =========
 Diluted (Note E)                    $  (0.01) $  (0.02) $  (0.01) $  (0.03)
                                     ========= ========= ========= =========
                                                                            
Weighted average common shares                                              
 outstanding:                                                               
 Basic                                152,085   151,560   152,085   145,466 
                                     ========= ========= ========= =========
 Diluted                              152,085   151,560   152,085   145,466 
                                     ========= ========= ========= =========
                                                                            
                                                                            
                        AEOLUS PHARMACEUTICALS, INC.                        
              CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS               
                                 (Unaudited)                                
                               (In thousands)                               
                                                                            
                                                         Six Months Ended   
                                                             March 31,      
                                                       ---------------------
                                                          2017       2016   
                                                       ---------- ----------
Cash flows from operating activities:                                       
  Net loss                                             $  (2,122) $  (1,662)
  Adjustments to reconcile net loss to net cash used                        
   in operating activities:                                                 
    Amortization of discount on note payable to                             
     shareholders                                              -        273 
    Accrued interest                                           -         12 
    Non-cash compensation                                     54         74 
    Change in assets and liabilities:                                       
      Accounts receivable                                    147        219 
      Deferred subcontractor cost                              -       (176)
      Prepaid expenses and other current assets               81       (111)
      Accounts payable and accrued expenses                 (334)      (567)
      Deferred revenue                                         -        183 
                                                       ---------- ----------
Net cash used in operating activities                     (2,174)    (1,755)
                                                                            
Cash flows from financing activities:                                       
Proceeds from issuance of common stock and common                           
 stock warrants, net                                           -      2,005 
Proceeds from issuance of preferred stock and common                        
 stock warrants, net                                           -      4,165 
                                                       ---------- ----------
Net cash provided by financing activities                      -      6,170 
Net increase (decrease) in cash and cash equivalents      (2,174)     4,415 
Cash and cash equivalents at beginning of period           3,155         94 
                                                       ---------- ----------
Cash and cash equivalents at end of period             $     981  $   4,509 
                                                       ========== ==========
                                                                            
Supplemental disclosure of non-cash financing                               
 activities:                                                                
Conversion of note payable to shareholders for common                       
 stock and warrants                                    $       -  $   1,000 
Conversion of accrued interest on note payable to                           
 shareholders for common stock and warrants            $       -  $      12 
Issuance of warrants for financing costs               $       -  $     266 
Deemed dividend on Series C preferred stock            $       -  $   2,486 
                                                                            

Contact:
John McManus
President and Chief Executive Officer
Aeolus Pharmaceuticals, Inc.
1-(949) 481-9825

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
Tapping into blockchain revolution early enough translates into a substantial business competitiveness advantage. Codete comprehensively develops custom, blockchain-based business solutions, founded on the most advanced cryptographic innovations, and striking a balance point between complexity of the technologies used in quickly-changing stack building, business impact, and cost-effectiveness. Codete researches and provides business consultancy in the field of single most thrilling innovative te...
Atmosera delivers modern cloud services that maximize the advantages of cloud-based infrastructures. Offering private, hybrid, and public cloud solutions, Atmosera works closely with customers to engineer, deploy, and operate cloud architectures with advanced services that deliver strategic business outcomes. Atmosera's expertise simplifies the process of cloud transformation and our 20+ years of experience managing complex IT environments provides our customers with the confidence and trust tha...
With the introduction of IoT and Smart Living in every aspect of our lives, one question has become relevant: What are the security implications? To answer this, first we have to look and explore the security models of the technologies that IoT is founded upon. In his session at @ThingsExpo, Nevi Kaja, a Research Engineer at Ford Motor Company, discussed some of the security challenges of the IoT infrastructure and related how these aspects impact Smart Living. The material was delivered interac...
CloudEXPO has been the M&A capital for Cloud companies for more than a decade with memorable acquisition news stories which came out of CloudEXPO expo floor. DevOpsSUMMIT New York faculty member Greg Bledsoe shared his views on IBM's Red Hat acquisition live from NASDAQ floor. Acquisition news was announced during CloudEXPO New York which took place November 12-13, 2019 in New York City. Our Silicon Valley 2019 schedule will showcase 200 keynotes, sessions, general sessions, power panels, and...
Intel is an American multinational corporation and technology company headquartered in Santa Clara, California, in the Silicon Valley. It is the world's second largest and second highest valued semiconductor chip maker based on revenue after being overtaken by Samsung, and is the inventor of the x86 series of microprocessors, the processors found in most personal computers (PCs). Intel supplies processors for computer system manufacturers such as Apple, Lenovo, HP, and Dell. Intel also manufactu...
Darktrace is the world's leading AI company for cyber security. Created by mathematicians from the University of Cambridge, Darktrace's Enterprise Immune System is the first non-consumer application of machine learning to work at scale, across all network types, from physical, virtualized, and cloud, through to IoT and industrial control systems. Installed as a self-configuring cyber defense platform, Darktrace continuously learns what is ‘normal' for all devices and users, updating its understa...
As you know, enterprise IT conversation over the past year have often centered upon the open-source Kubernetes container orchestration system. In fact, Kubernetes has emerged as the key technology -- and even primary platform -- of cloud migrations for a wide variety of organizations. Kubernetes is critical to forward-looking enterprises that continue to push their IT infrastructures toward maximum functionality, scalability, and flexibility. As they do so, IT professionals are also embr...
The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long development cycles that produce software that is obsolete at launch. DevOps may be disruptive, but it is essential. DevOpsSUMMIT at CloudEXPO expands the DevOps community, enable a wide sharing of knowledge, and educate delegates and technology providers alike.
Cloud-Native thinking and Serverless Computing are now the norm in financial services, manufacturing, telco, healthcare, transportation, energy, media, entertainment, retail and other consumer industries, as well as the public sector. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long development cycles that pro...
At CloudEXPO Silicon Valley, June 24-26, 2019, Digital Transformation (DX) is a major focus with expanded DevOpsSUMMIT and FinTechEXPO programs within the DXWorldEXPO agenda. Successful transformation requires a laser focus on being data-driven and on using all the tools available that enable transformation if they plan to survive over the long term. A total of 88% of Fortune 500 companies from a generation ago are now out of business. Only 12% still survive. Similar percentages are found throug...
OpsRamp is an enterprise IT operation platform provided by US-based OpsRamp, Inc. It provides SaaS services through support for increasingly complex cloud and hybrid computing environments from system operation to service management. The OpsRamp platform is a SaaS-based, multi-tenant solution that enables enterprise IT organizations and cloud service providers like JBS the flexibility and control they need to manage and monitor today's hybrid, multi-cloud infrastructure, applications, and wor...
Apptio fuels digital business transformation. Technology leaders use Apptio's machine learning to analyze and plan their technology spend so they can invest in products that increase the speed of business and deliver innovation. With Apptio, they translate raw costs, utilization, and billing data into business-centric views that help their organization optimize spending, plan strategically, and drive digital strategy that funds growth of the business. Technology leaders can gather instant recomm...
The Master of Science in Artificial Intelligence (MSAI) provides a comprehensive framework of theory and practice in the emerging field of AI. The program delivers the foundational knowledge needed to explore both key contextual areas and complex technical applications of AI systems. Curriculum incorporates elements of data science, robotics, and machine learning-enabling you to pursue a holistic and interdisciplinary course of study while preparing for a position in AI research, operations, ...
CloudEXPO has been the M&A capital for Cloud companies for more than a decade with memorable acquisition news stories which came out of CloudEXPO expo floor. DevOpsSUMMIT New York faculty member Greg Bledsoe shared his views on IBM's Red Hat acquisition live from NASDAQ floor. Acquisition news was announced during CloudEXPO New York which took place November 12-13, 2019 in New York City.
Industry after industry is under siege as companies embrace digital transformation (DX) to disrupt existing business models and disintermediate their competitor’s customer relationships. But what do we mean by “Digital Transformation”? The coupling of granular, real-time data (e.g., smartphones, connected devices, smart appliances, wearables, mobile commerce, video surveillance) with modern technologies (e.g., cloud native apps, big data architectures, hyper-converged technologies, artificial in...